Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation

Bone Marrow Transplantation

Volumn 23, Issue 1, 1999, Pages 27-33

  Salazar, R ^c   Sola C ^b   Maroto, P ^c   Tabernero, J M ^c   Brunet, J ^c   Verger, G ^c   Valenti V ^c   Cancelas, J A ^a   Ojeda, B ^c   Mendoza, L ^c   Rodriguez M ^c   Montesinos, J ^c   Lopez Lopez J J ^c  

^a Institut de Recerca Oncologica   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c NONE

Author keywords

Bacteremia; Fever; High dose chemotherapy; Imipenem; Infectious complications; PBSC transplantation

Indexed keywords

ACICLOVIR; AMIKACIN; AMPHOTERICIN B LIPID COMPLEX; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CIPROFLOXACIN; IMIPENEM; ITRACONAZOLE; VANCOMYCIN;

ADULT; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; CATHETER INFECTION; CELLULITIS; CLINICAL TRIAL; DRUG EFFICACY; ENTEROCOLITIS; FEMALE; FEVER; GRAM POSITIVE BACTERIUM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; INFECTIOUS COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTION; SOLID TUMOR; STAPHYLOCOCCUS EPIDERMIDIS; THROMBOCYTE COUNT;

EID: 0033009293     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701520     Document Type: Article

References (49)

1. Gulanti SC, Yahalom J, Portlock CS. Autologous bone marrow transplantation: current status and future directions. Ann Intern Med 1991; 110: 51-65.
2. Holland HK, Saral R. Infectious diseases. In: Armitage JO, Antman KH (eds). High-dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells. Williams & Wilkins: Baltimore, 1995, pp 508-526.
3. Schimpff SC. Infections in the cancer patient. Diagnosis, prevention, and treatment. In: Mandell GL, Bennet JE, Dolin E (eds). Principles and Practice of Infectious Diseases, 4th edn. Churchill Livingstone: New York, 1995, pp 2666-2675.
4. Nosanchuk JD, Sepkowitz KA, Pearse RN et al. Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma. Bone Marrow Transplant 1996; 18: 355-359.
5. Mossad SB, Longworth DL, Goormastic M et al. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 1996; 18: 265-271.
6. To LB, Dysson PG, Juttner CA. Cell-dose effect in circulating stem cell transplantation. Lancet 1986; 2: 402-405.
7. Kessinger A, Armitage JO. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 1991; 77: 211-213.
8. Reiffers J, Castaigne S, Tilly H et al. Hematopoietic reconstitution after autologous blood stem cell transplantation: a report of 45 cases. Plasma Ther Transfus Technol 1987; 8: 360-365.
9. Schwartzberg L, Birch R, Blanco R et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 1993; 11: 369-374.
10. Klumpp TR, Mangan KF, Goldberg SL et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 13: 1323-1327.
11. Hornedo J, Sola C, Solano C et al. Multicenter, prospective, randomized study of the role of granulocyte colony-stimulating factor (G-CSF) in the post transplant period following high-dose chemotherapy (HDC), supported with G-CSF-mobilized, peripheral blood stem cells (PBSC), in breast cancer patients. Ann Oncol 1996; 7 (Suppl. 5): 63.
12. Peters WP, Rosner G, Ross M et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-1719.
13. Schwartzberg L, Birch R, Weaver C et al. The effect of varying durations of granulocyte colony stimulating factor (G-CSF) on neutrophil engraftment and supportive care following peripheral blood progenitor cell (PBPC) infusion. Blood 1994; 84: 91a.
14. Pizzo PA. Empirical therapy and prevention of infection in the immunocompromised host. In: Mandell GL, Bennet JE, Dolin R (eds). Principles and Practice of Infectious Diseases, 4th edn. Churchill Livingstone: New York, 1995, pp 2686-2696.
15. De Pauw BE, Donnelly JP, De Witte T et al. Options and limitations of long-term oral ciprofloxacin as antibacterial prophylaxis in allogenic bone marrow transplant recipients. Bone Marrow Transplant 1990; 5: 179-182.
16. Wimperis JZ, Baglin TP, Marcus RE et al. An assessment of the efficacy of antimicrobial prophylaxis in bone marrow autografts. Bone Marrow Transplant 1991; 8: 363-367.
17. Lew MA, Kehoe K, Ritz J et al. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 1991; 51: 630-636.
18. Goodman JI, Winston DJ, Greenfield RA et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 1992; 326: 845-851.
19. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplastin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-110.
20. Motzer RJ, Gulati SC, Crown JP et al. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 1992; 69: 550-556.
21. Gaspard MH, Maraninchi D, Stoppa AM et al. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. Cancer Chemother Pharmacol 1988; 22: 256-262.
22. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
23. Bone RC. Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions. Ann Intern Med 1991; 114: 332-333.
24. Raad II, Bodey GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis 1992; 15: 197-210.
25. Greene JN. Catheter-related complications of cancer therapy. Infect Dis Clin North Am 1996; 10: 255-295.
26. Taylor KMcD, Jagannath S, Spitzer G et al. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 1989; 7: 1791-1799.
27. Sheridan WP, Morstyn G, Wolf M et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; 2: 891-895.
28. Linch DC, Scarffe H, Proctor S et al. Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 1993; 11: 307-311.
29. Gisselbrecht C, Prentice HG, Bacigalupo A et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 1994; 43: 696-700.
30. Winston DJ, Ho WG, Bruckner DA et al. Ofloxacin versus vancomycin/polymyxin for prevention of infection in granulocytopenic patients. Am J Med 1990; 88: 36-42.
31. Spitzer G, Dunphy FR II, Velçásquez WS et al. Filgrastim (r-metHuG-CSF) in bone marrow and peripheral blood cell transplantation. In: Morstyn G, Dexter TM (eds). Filgrastim (r-metHuG-CSF) in Clinical Practice. Marcel Decker: New York, 1994, pp 173-195.
32. Holland K, Dix SP, Geller RB et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. J Clin Oncol 1996; 14: 1156-1164.
33. Benson K, Fields K, Hiemenz J et al. The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding. Semin Oncol 1993; 20: 102-109.
34. Shimazaki C, Oku N, Uchiyama H et al. Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1994; 13: 271-275.
35. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): analysis of factors correlating with tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
36. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
37. McWhinney PHM, Kibbler CC, Hamon MD et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993; 17: 397-404.
38. Thunnissen PLM, Sizoo W, Hendriks WDH. Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients. Neth J Med 1991; 39: 84-91.
39. van't Wout JW, Novakova I, Verhagen CAH et al. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect 1991; 22: 45-52.
40. Tricot G, Joosten E, Boogaerts MA et al. Ketoconazole vs itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis 1987; 9 (Suppl. 1): S94-99.
41. Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycosis. Drugs 1989; 37: 310-344.
42. Persat F, Marzullo C, Guyotat D et al. Plasma itraconazole concentrations in neutropenic patients after high-dose treatment. Eur J Cancer 1992; 28A: 838-841.
43. Winston DJ, Winston H, Bruckner DA et al. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991; 115: 849-859.
44. Cometta A, Calandra T, Gaya H et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996; 40: 1108-1115.
45. Rolston KVI, Berkey P, Bodey GP et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992; 152: 283-291.
46. Benezra D, Kiehn TE, Gold J et al. Prospective study of infections in indwelling central venous catheters using quantitative blood cultures. Am J Med 1988; 85: 495-498.
47. Elting LS, Bodey GP. Septicemia due to Xanthomas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter-related infections. Medicine 1990; 69: 296-306.
48. Gilbert C, Meisenberg B, Vredenburgh J et al. Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 1994; 12: 1005-1011.
49. Brugger W, Heimfeld S, Berenson RJ et al. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. New Engl J Med 1995; 333: 283-287.